Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.
Valneva said regaining full rights to the vaccine will allow the company to “assume direct control over its supply chain and commercialization for endemic high-risk countries
The sudden subsequent decision to suspend IXCHIQ is based on updated VAERS data
The agency concluded that for people of all ages, IXCHI should be administered when there is a significant risk of chikungunya infection
This marks an expansion of the companies' existing collaboration and further validates the use of Albumedix Recombumin rHA products in the manufacturing process and final formulation of critical vaccines
The grants are expected to be received over the next three years, commencing March 2022
It is a recombinant nanoparticle protein-based vaccine
Filing for WHO Emergency Use Authorisation this month
Subscribe To Our Newsletter & Stay Updated
